Vnitr Lek 2012, 58(6):466-472

Oxidative stress in patients on regular hemodialysis and peritoneal dialysis

J. Vostálová1, A. Galandáková1,*, P. Štrebl2, J. Zadražil2
1 Ústav lékařské chemie a biochemie Lékařské fakulty UP Olomouc, přednostka prof. RNDr. Jitka Ulrichová, CSc.
2 III. interní nefrologická, revmatologická a endokrinologická klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc.

Hemodialysis and peritoneal dialysis are methods of blood purification, which partially replaced excretory renal function in patients with chronic renal failure, which was depleted regime, dietary and pharmaco-therapeutic remedy, and who are not eligible for kidney transplantation. Both two methods are accompanied by increased oxidative stress. In peritoneal dialysis particularly the composition of dialysis solution contributes to oxidative stress. In extracorporeal hemodialysis the oxidative stress is associated with the character of hemodialysis membranes, non-specific loss of low molecular weight antioxidants, activation of leukocytes (oxidative burst), feroteraphy, supplementation with low molecular weight antioxidants and other factors. To improve and maintain the quality of life of dialysis patients, the continuous monitoring of oxidative stress-related parameters as non-traditional risk factors for cardiovascular complications development is suitable.

Keywords: oxidative stress; antioxidants; kidney; hemodialysis; peritoneal dialysis

Received: November 10, 2011; Accepted: February 20, 2012; Published: June 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vostálová J, Galandáková A, Štrebl P, Zadražil J. Oxidative stress in patients on regular hemodialysis and peritoneal dialysis. Vnitr Lek. 2012;58(6):466-472.
Download citation

References

  1. Teplan V et al. Praktická nefrologie. Praha: Grada 2006.
  2. Del Vecchio L, Locatelli F, Carini M. What we know about oxidative stress in patients with chronic kidney disease on dialysis - clinical effects, potential treatment, and prevention. Semin Dial 2011; 24: 56-64. Go to original source... Go to PubMed...
  3. Vostálová J, Galandáková A, Štrebl P et al. Oxidační stres u pacientů s onemocnění ledvin. Vnitř Lék 2012; 58: 202-207. Go to PubMed...
  4. Kadkhodaee M, Hemmati M, Zahmatkesh M et al. Assessment of plasma antioxidant status in hemodialysis patients. Ther Apher Dial 2008; 12: 147-151. Go to original source... Go to PubMed...
  5. Coaccioli S, Standoli ML, Biondi R et al. Assessment of the oxidative stress markers in patients with chronic renal insufficiency undergoing dialysis treatment. Clin Ter 2010; 161: 441-444. Go to PubMed...
  6. Caussé E, Ribes D, Longlune N et al. Aminothiols and allantoin in chronic dialysis patients: effects of hemodialysis sessions. Clin Nephrol 2010; 73: 51-57. Go to original source... Go to PubMed...
  7. Witasp A, Carrero JJ, Heimbürger O et al. Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients. J Intern Med 2011; 269: 410-419. Go to original source... Go to PubMed...
  8. Mekki K, Taleb W, Bouzidi N et al. Effect of hemodialysis and peritoneal dialysis on redox status in chronic renal failure patients: a comparative study. Lipids Health Dis 2010; 9: 93. Go to original source... Go to PubMed...
  9. Montazerifar F, Hashemi M, Karajibani M et al. Hemodialysis alters lipid profiles, total antioxidant capacity, and vitamins A, E, and C concentrations in humans. J Med Food 2010; 13: 1490-1493. Go to original source... Go to PubMed...
  10. Michelis R, Kristal B, Snitkovsky T et al. Oxidative modifications impair albumin quantification. Biochem Biophys Res Commun 2010; 401: 137-142. Go to original source... Go to PubMed...
  11. Libetta C, Sepe V, Esposito P et al. Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clin Biochem 2011; 44: 1189-1198. Go to original source... Go to PubMed...
  12. Mitrogianni Z, Barbouti A, Galaris D et al. Oxidative modification of albumin in predialysis, hemodialysis, and peritoneal dialysis patients. Nephron Clin Pract 2009; 113: 234-240. Go to original source... Go to PubMed...
  13. Choi JY, Yoon YJ, Choi HJ et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol Dial Transplant 2010; 26: 1304-1313. Go to original source... Go to PubMed...
  14. Filiopoulos V, Hadjiyannakos D, Takouli L et al. Inflammation and oxidative stress in end-stage renal disease patients treated with hemodialysis or peritoneal dialysis. Int J Artif Organs 2009; 32: 872-882. Go to original source... Go to PubMed...
  15. Castoldi G, Antolini L, Bombardi C et al. Oxidative stress biomarkers and chromogranin A in uremic patients: effects of dialytic treatment. Clin Biochem 2010; 43: 1387-1392. Go to original source... Go to PubMed...
  16. Fassett RG, Driver R, Healy H et al. Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients - an observational study. BMC Nephrol 2009; 10: 8-14. Go to original source... Go to PubMed...
  17. Opatrná S. Peritoneální dialyzační roztoky druhé generace: preklinické studie a klinické zkušenosti. Plzeň: Euroverlag 2009.
  18. Rabbani N, Thornalley PJ. Quantitation of markers of protein damage by glycation, oxidation, and nitration in peritoneal dialysis. Perit Dial Int 2009; 29 (Suppl 2): S51-S56. Go to original source... Go to PubMed...
  19. Lai KN, Leung JC. Inflammation in peritoneal dialysis. Nephron Clin Pract 2010; 116: 11-18. Go to original source... Go to PubMed...
  20. Kocak H, Gumuslu S, Sahin E et al. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Nephrology (Carlton) 2009; 14: 273-280. Go to original source... Go to PubMed...
  21. Tarng DC, Wen Chen T, Huang TP et al. Increased oxidative damage to peripheral blood leukocyte DNA in chronic peritoneal dialysis patients. J Am Soc Nephrol 2002; 13: 1321-1330. Go to original source... Go to PubMed...
  22. Ignace S, Fouque D, Arkouche W et al. Preserved residual renal function is associated with lower oxidative stress in peritoneal dialysis patients. Nephrol Dial Transplant 2009; 24: 1685-1689. Go to original source... Go to PubMed...
  23. Furuya R, Kumagai H, Odamaki M et al. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin Pract 2009; 112: c255-c261. Go to original source... Go to PubMed...
  24. Singer R, Rhodes HC, Chin G et al. High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. Nephrology (Carlton) 2008; 13: 17-22. Go to original source... Go to PubMed...
  25. Guo CH, Wang CL, Chen PC et al. Linkage of some trace elements, peripheral blood lymphocytes, inflammation, and oxidative stress in patients undergoing either hemodialysis or peritoneal dialysis. Perit Dial Int 2011; 31: 583-591. Go to original source... Go to PubMed...
  26. Demirci S, Sekeroğlu MR, Noyan T et al. The importance of oxidative stress in patients with chronic renal failure whose hypertension is treated with peritoneal dialysis. Cell Biochem Funct 2011; 29: 249-254. Go to original source... Go to PubMed...
  27. Włodek P, Marcykiewicz B, Iciek M et al. Thiol levels, protein carbonylation and anaerobic sulfur metabolism in erythrocytes of peritoneal dialysis and predialysis patients. Nephrology (Carlton) 2010; 15: 755-761. Go to original source... Go to PubMed...
  28. Chung AW, Yang HH, Kim JM et al. Arterial stiffness and functional properties in chronic kidney disease patients on different dialysis modalities: an exploratory study. Nephrol Dial Transplant 2010; 25: 4031-4041. Go to original source... Go to PubMed...
  29. Sundl I, Roob JM, Meinitzer A et al. Antioxidant status of patients on peritoneal dialysis: associations with inflammation and glycoxidative stress. Perit Dial Int 2009; 29: 89-101. Go to original source... Go to PubMed...
  30. Eiselt J, Racek J, Opatrný jr. K. Volné radikály a mimotělní náhrada funkce ledvin. Vnitř Lék 1999; 45: 319-324. Go to PubMed...
  31. Locatelli F, Canaud B, Eckardt KU et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280. Go to original source... Go to PubMed...
  32. Lim PS, Wei YH, Yu YL et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-2687. Go to original source... Go to PubMed...
  33. Hörl WH. Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol 2007; 22: 480-489. Go to original source... Go to PubMed...
  34. Tarng DC, Huang TP, Wei YH et al. 8-hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 934-944. Go to original source... Go to PubMed...
  35. Stuard S, Bonomini M, Settefrati N et al. Platelet-neutrophil interactions during hemodialysis: a proposed biocompatibility approach. Int J Artif Organs 1998; 21: 75-82. Go to original source...
  36. Itoh S, Susuki C, Tsuji T. Platelet activation through interaction with hemodialysis membranes induces neutrophils to produce reactive oxygen species. J Biomed Mater Res A 2006; 77: 294-303. Go to original source... Go to PubMed...
  37. Riegel W, Leverenz K, Schollmeyer P et al. Plasma levels of main granulocyte components during hemodialysis: effects of immunosuppression. Nephron 1987; 46: 161-166. Go to original source... Go to PubMed...
  38. Ono K, Ueki K, Inose K et al. Plasma levels of myeloperoxidase and elastase are differentially regulated by hemodialysis membranes and anticoagulants. Res Commun Mol Pathol Pharmacol 2000; 108: 341-349. Go to PubMed...
  39. Wu CC, Chen JS, Wu WM et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant 2005; 20: 1134-1139. Go to original source... Go to PubMed...
  40. Krieter DH, Morgenroth A, Barasinski A et al. Effects of a polyelectrolyte additive on the selective dialysis membrane permeability for low-molecular-weight proteins. Nephrol Dial Transplant 2007; 22: 491-499. Go to original source... Go to PubMed...
  41. Morena M, Delbosc S, Dupuy AM et al. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005; 9: 37-46. Go to original source... Go to PubMed...
  42. Lubrano R, Taccone-Gallucci M, Piazza A et al. Vitamin E supplementation and oxidative status of peripheral blood mononuclear cells and lymphocyte subsets in hemodialysis patients. Nutrition 1992; 8: 94-97.
  43. Buoncristiani U, Galli F, Rovidati S et al. Oxidative damage during hemodialysis using a vitamin-E-modified dialysis membrane: a preliminary characterization. Nephron 1997; 77: 57-61. Go to original source... Go to PubMed...
  44. Galli F, Rovidati S, Chiarantini L et al. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int 1998; 54: 580-589. Go to original source... Go to PubMed...
  45. Cruz DN, de Cal M, Ronco C. Oxidative stress and anemia in chronic hemodialysis: the promise of bioreactive membranes. Contrib Nephrol 2008; 161: 89-98. Go to original source... Go to PubMed...
  46. Tarng DC, Huang TP, Liu TY et al. Effect of vitamin E-bonded membrane on the 8-hydroxy 2'-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int 2000; 58: 790-799. Go to original source... Go to PubMed...
  47. Cruz DN, De Cal M, Garzotto F et al. Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study. Int J Artif Organs 2008; 31: 545-552. Go to original source... Go to PubMed...
  48. Eiselt J, Racek J, Trefil L et al. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artif Organs 2001; 25: 430-436. Go to original source... Go to PubMed...
  49. Yang CC, Hsu SP, Wu MS et al. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006; 69: 706-714. Go to original source... Go to PubMed...
  50. Mune M, Yukawa S, Kishino M et al. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int Suppl 1999; 71: S126-S129. Go to original source...
  51. Morena M, Jaussent I, Chalabi L et al. Biocompatibility of heparin-grafted hemodialysis membranes: Impact on monocyte chemoattractant protein-1 circulating level and oxidative status. Hemodial Int 2010; 14: 403-410. Go to original source... Go to PubMed...
  52. Alhamdani MS, Al-Najjar AF, Al-Kassir AH. The effect of hemodialysis and dialyzer biocompatibility on erythrocyte glutathione-defense system in chronic hemodialysis patients. Int J Artif Organs 2005; 28: 576-582. Go to original source... Go to PubMed...
  53. Kayabasi H, Sit D, Atay AE et al. Parameters of oxidative stress and echocardiographic indexes in patients on dialysis therapy. Ren Fail 2010; 32: 328-334. Go to original source... Go to PubMed...
  54. Pawlak K, Pawlak D, Mysliwiec M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem 2005; 38: 700-705. Go to original source... Go to PubMed...
  55. Akiyama S, Inagaki M, Tsuji M et al. mRNA study on Cu/Zn superoxide dismutase induction by hemodialysis treatment. Nephron Clin Pract 2005; 99: c107-c114. Go to original source... Go to PubMed...
  56. Olszewska M. The effect of hemodialysis on some parameters of the antioxidant system in the blood of patients with chronic renal failure. Ann Acad Med Stetin 2004; 50: 41-52.
  57. Hakim RM. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44: 484-494. Go to original source... Go to PubMed...
  58. Štípek S et al. Antioxidanty a volné radikály ve zdraví a v nemoci. Praha: Grada 2000.
  59. Ward RA, McLeish KR. Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 2003; 27: 230-236. Go to original source... Go to PubMed...
  60. Hurst JK, Barrette WC jr. Leukocytic oxygen activation and microbicidal oxidative toxins. Crit Rev Biochem Mol Biol 1989; 24: 271-328. Go to original source... Go to PubMed...
  61. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009; 22: 636-643. Go to original source... Go to PubMed...
  62. Heinecke JW. Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 1999; 133: 321-325. Go to original source... Go to PubMed...
  63. Himmelfarb J, Mc Menamin ME, Loseto G et al. Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 2001; 31: 1163-1169. Go to original source... Go to PubMed...
  64. Bargnoux AS, Morena M, Badiou S et al. Groupe de travail de la SFBC: Biologie des fonctions renales et de l'insuffisance renale. Carbonyl stress and oxidatively modified proteins in chronic renal failure. Ann Biol Clin (Paris) 2009; 67: 153-158. Go to original source...
  65. Deicher R, Hörl WH. Vitamin C in chronic kidney disease and hemodialysis patients. Kidney Blood Press Res 2003; 26: 100-106. Go to original source... Go to PubMed...
  66. Keven K, Kutlay S, Nergizoglu G et al. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 2003; 41: 1233-1239. Go to original source... Go to PubMed...
  67. Weissinger EM, Nguyen-Khoa T, Fumeron C et al. Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics 2006; 6: 993-1000. Go to original source... Go to PubMed...
  68. Yang CC, Hsu SP, Wu MS et al. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006; 69: 706-714. Go to original source... Go to PubMed...
  69. Attallah N, Osman-Malik Y, Frinak S et al. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 2006; 47: 644-654. Go to original source... Go to PubMed...
  70. Fumeron C, Nguyen-Khoa T, Saltiel C et al. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant 2005; 20: 1874-1879. Go to original source... Go to PubMed...
  71. Chan D, Irish A, Croft KD et al. Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 234-235. Go to original source... Go to PubMed...
  72. Chen WT, Lin YF, Yu FC et al. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels. Am J Kidney Dis 2003; 42: 158-166. Go to original source... Go to PubMed...
  73. Deicher R, Ziai F, Bieglmayer C et al. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 1811-1818. Go to original source... Go to PubMed...
  74. De Vriese AS, Borrey D, Mahieu E et al. Oral vitamin C administration increases lipid peroxidation in hemodialysis patients. Nephron Clin Pract 2008; 108: c28-c34. Go to original source... Go to PubMed...
  75. Deved V, Poyah P, James MT et al. Alberta Kidney Disease Network. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1089-1097. Go to original source... Go to PubMed...
  76. Washio K, Inagaki M, Tsuji M et al. Oral vitamin C supplementation in hemodialysis patients and its effect on the plasma level of oxidized ascorbic acid and Cu/Zn superoxide dismutase, an oxidative stress marker. Nephron Clin Pract 2008; 109: c49-c54. Go to original source... Go to PubMed...
  77. Hodkova M, Dusilova Sulkova S, Kalousova M et al. Influence of oral vitamin E therapy on micro-inflammation and cardiovascular disease markers in chronic hemodialysis patients. Ren Fail 2006; 28: 395-399. Go to original source... Go to PubMed...
  78. Akiyama S, Inagaki M, Tsuji M et al. Comparison of effect of vitamin E-coated dialyzer and oral vitamin E on hemodialysis-induced Cu/Zn-superoxide dismutase. Am J Nephrol 2005; 25: 500-506. Go to original source... Go to PubMed...
  79. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-1218. Go to original source... Go to PubMed...
  80. Kamgar M, Zaldivar F, Vaziri ND et al. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc 2009; 101: 336-344. Go to original source... Go to PubMed...
  81. Zachara BA, Gromadzińska J, Wasowicz W et al. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 2006; 53: 663-677. Go to original source... Go to PubMed...
  82. Taccone-Gallucci M, Noce A, Bertucci P et al. Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients. J Trace Elem Med Biol 2010; 24: 27-30. Go to original source... Go to PubMed...
  83. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007; 18: 382-393. Go to original source... Go to PubMed...
  84. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076.
  85. Sun Y, Stidley CA, Harford AM et al. Increased cardiovascular and infectious deaths in hemodialysis (HD) patients treated with high dose intravenous iron therapy. J Am Soc Nephrol 2002; 13: 434A.
  86. Bayés B, Pastor MC, Bonal J et al. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis - role of seniority and intravenous ferrotherapy: analysis at 4 Years of follow-up. Nephrol Dial Transplant 2006; 21: 984-990. Go to original source... Go to PubMed...
  87. Swarnalatha G, Ram R, Neela P et al. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. Saudi J Kidney Dis Transpl 2010; 21: 852-858. Go to PubMed...
  88. Hodkova M, Dusilova Sulkova S, Skalicka A et al. Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients. Ren Fail 2005; 27: 135-141. Go to original source... Go to PubMed...
  89. Sommerburg O, Grune T, Hampl H et al. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 1998; 13: 2583-2587. Go to original source... Go to PubMed...
  90. Ludat K, Sommerburg O, Grune T et al. Oxidation parameters in complete correction of renal anemia. Clin Nephrol 2000; 53: S30-S35. Go to PubMed...
  91. Pawlak K, Pawlak D, Mysliwiec M. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thromb Res 2007; 120: 797-803. Go to original source... Go to PubMed...
  92. Monostori P, Hracskó Z, Karg E et al. Erythropoiesis-stimulating agent withdrawal and oxidative stress in hemodialysis. Clin Nephrol 2009; 71: 521-526. Go to original source... Go to PubMed...
  93. Swant J, Nair S, Redkar N. Oxidative stress and serum paraoxonase activity in patients on maitenance hemodialysis. Internet J Nephrol 2010; 6. Go to original source...
  94. Gugliucci A, Kinugasa E, Kotani K et al. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med 2011, 49: 61-67. Go to original source... Go to PubMed...
  95. Granata S, Zaza G, Simone S et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009; 10: 388-400. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.